E5564, a lipid A analogue, is a potent antagonist of lipopolysaccharide (LPS). Clinically, E5564 was developed as a possible therapy for treatment of sepsis and septic shock. Surface plasmon resonance (SPR) analysis indicates that E5564 binds to LPS binding protein (LBP), in a manner similar to LPS. Gel-filtration radioactive chromatograms of [14C]-E5564 in plasma revealed that E5564 initially distributes to the lipoprotein fractions, separated from high-density lipoprotein (HDL); the bound fraction is then released and binds to HDL. Similar results were obtained by heparin-manganese precipitation. At doses of E5564 relevant to its clinical use (i.e. 6 µg/ml), antibodies against LBP did not influence either the distribution of E5564 to non-HDL lipoprotein fractions or the transfer of E5564 from non-HDLs to HDL. Under these conditions, transfer of E5564 to HDL occurs similarly in the plasma of LBP knockout (KO) mice as in the plasma from wild-type mice. In addition, plasma clearance of E5564 in LBP KO mice is similar to that of wild-type mice. Thus, LBP binds E5564 in a manner similar to LPS, but does not play a role in E5564 redistribution/binding to lipoprotein and plasma clearance.
Rietschel ET , Kirikae T., Schade F. et al. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J1994; 8: 217—225.
3.
Raetz CRBiochemistry of endotoxins. Annu Rev Biochem1990; 59: 129—170.
4.
Zähringer U., Lindner B., Rietschel ETChemical structure of lipid A: Recent advances in structural analysis of biologically active molecules. In: Brade H, Opal SM, Vogel SN, Morrison DC. (eds) Endotoxin in Health and Disease. New York: Marcel Dekker , 1999; 93—114.
5.
Loppnow H., Libby P., Freudenberg M., Krauss JH, Weckesser J., Mayer H.Cytokine induction by lipopolysaccharide (LPS) corresponds to lethal toxicity and is inhibited by nontoxic Rhodobacter capsulatus LPS. Infect Immun1990; 58: 3743—3750.
6.
Takayama K., Qureshi N., Beutler B., Kirkland TNDiphosphoryl lipid A from Rhodopseudomonas sphaeroides ATCC 17023 blocks induction of cachectin in macrophages by lipopolysaccharide. Infect Immun1989; 57: 1336—1338.
7.
Qureshi N., Takayama K., Kurtz R.Diphosphoryl lipid A obtained from the nontoxic lipopolysaccharide of Rhodopseudomonas sphaeroides is an endotoxin antagonist in mice. Infect Immun1991; 59: 441—444.
8.
Aida Y., Kusumoto K., Nakatomi K., Takada H., Pabst MJ, Maeda K.An analogue of lipid A and LPS from Rhodobacter sphaeroides inhibits neutrophil responses to LPS by blocking receptor recognition of LPS and by depleting LPS-binding protein in plasma. J Leukoc Biol1995; 58: 675—682.
9.
Rossignol DP, Hawkins LD, Christ WJ et al. Synthetic endotoxin antagonists. In: Brade H, Opal SM, Vogel SN, Morrison DC. (eds) Endotoxin in Health and Disease. New York : Marcel Dekker, 1999; 699—717.
10.
Rossignol DP , Lynn M.Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue. J Endotoxin Res2002; 8: 483—488.
11.
Lynn M., Wong YN, Wheeler JL et al. Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia. J Pharmacol Exp Ther2004; 308: 175—181.
12.
Wong YN, Rossignol D., Rose JR, Kao R., Carter A, Lynn M. Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study. J Clin Pharmacol2003; 43: 735—742.
13.
Kaneko K., Ueda R., Kikuchi K., Sano Y., Yoshimura T.Quantitative determination of a potent lipopolysaccharide antagonist, E5564, in rat and dog plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl1999; 736: 67—75.
14.
Kaneko K., Ueda R., Nemoto H., Iijima H., Yoshimura T.Disposition of a synthetic analogue of lipid A (E5564) in rats. Xenobiotica2003; 33: 323—339.
15.
Mathison JC , Ulevitch RJThe clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. J Immunol1979; 123: 2133—2143.
16.
Mathison JC , Ulevitch RJUptake and subcellular localization of bacterial lipopolysaccharide in the adrenal gland. Am J Pathol1985; 120: 79—86.
17.
Acton S., Rigotti A., Landschulz KT, Xu S., Hobbs HH, Krieger M.Identification of scavenger receptor SR-BI as a high density lipoprotein receptor . Science1996; 271: 518—520.
18.
Harris HW, Grunfeld C., Feingold KR et al. Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death. J Clin Invest1993; 91: 1028—1034.
19.
Hailman E., Lichenstein HS, Wurfel MM et al. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med1994; 179: 269—277.
20.
Wurfel MM, Hailman E., Wright SDSoluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. J Exp Med1995; 181: 1743—1754.
21.
Tobias PS, Soldau K., Gegner JA, Mintz D., Ulevitch RJLipopolysaccharide binding protein-mediated complexation of lipopolysaccharide with soluble CD14. J Biol Chem1995; 270: 10482—10488.
22.
Rose JR, Mullarkey MA, Christ WJ et al. Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins. Antimicrob Agents Chemother2000; 44: 504—510.
23.
Yu B., Wright SDCatalytic properties of lipopolysaccharide (LPS) binding protein. Transfer of LPS to soluble CD14. J Biol Chem1996; 271: 4100—4105.
24.
de Haas CJ, van Leeuwen HJ, Verhoef J., van Kessel KP, van Strijp JAAnalysis of lipopolysaccharide (LPS)-binding characteristics of serum components using gel filtration of FITClabeled LPS. J Immunol Methods2000; 242: 79—89.
25.
Levels JH, Abraham PR, van den Ende A., van Deventer SJDistribution and kinetics of lipoprotein-bound endotoxin. Infect Immun2001; 69: 2821—2828.
26.
Fägerstam LG , Frostell Å. , Karlsson R. et al. Detection of antigen-antibody interactions by surface plasmon resonance. Application to epitope mapping. J Mol Recog1990; 3: 208—214.
27.
Löfås S., Johnsson B.A novel hydrogel matrix on gold surfaces in surface plasmon resonance sensors for fast and efficient covalent immobilization of ligands. J Chem Soc Chem Commun1990; 21: 1526—1528.
28.
Wurfel MM, Monks BG, Ingalls RR et al. Targeted deletion of the lipopolysaccharide (LPS)-binding protein gene leads to profound suppression of LPS responses ex vivo, whereas in vivo responses remain intact. J Exp Med1997; 186: 2051—2056.
29.
Allain CC, Poon LS, Chan CS, Richmond W., Fu PCEnzymatic determination of total serum cholesterol. Clin Chem1974; 20: 470—475.
30.
Doumas BT, Watson WA, Biggs HGAlbumin standards and the measurement of serum albumin with bromocresol green . Clin Chim Acta1971; 31: 87—96.
31.
Demacker PN , Hessels M., Toenhake-Dijkstra H., Baadenhuijsen H.Precipitation methods for high-density lipoprotein cholesterol measurement compared, and final evaluation under routine operating conditions of a method with a low sample-to-reagent ratio. Clin Chem1997; 43: 663—668.
32.
David SA, Balaram P., Mathan VICharacterization of the interaction of lipid A and lipopolysaccharide with human serum albumin: implication for an endotoxin carrier function for albumin . J Endotoxin Res1995; 2: 99—106.
33.
Jurgens G., Muller M., Garidel P. et al. Investigation into the interaction of recombinant human serum albumin with Re-lipopolysaccharide and lipid A. J Endotoxin Res2002; 8: 115—126.
34.
Vreugdenhil AC, Snoek AM, van't Veer C., Greve JW, Buurman WALPS-binding protein circulates in association with apoBcontaining lipoproteins and enhances endotoxin-LDL/VLDL interaction . J Clin Invest2001; 107: 225—234.
35.
Hampton RY, Raetz CRMacrophage catabolism of lipid A is regulated by endotoxin stimulation . J Biol Chem1991; 266: 19499—19509.
36.
Schletter J. , Heine H., Ulmer AJ, Rietschel ETMolecular mechanisms of endotoxin activity . Arch Microbiol1995 ; 164: 383—389.
37.
Munford RS, Hall CL, Dietschy JMBinding of Salmonella typhimurium lipopolysaccharides to rat high-density lipoproteins. Infect Immun1981; 34: 835—843.
38.
Van Lenten BJ , Fogelman AM, Haberland ME, Edwards PAThe role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide . Proc Natl Acad Sci USA1986; 83: 2704—2708.
